Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Expression of a Novel Chimeric Inhibitory Receptor Attenuates CD19 CAR T Cells: A Promising Strategy for Toxicity Mitigation

Dustin A Cobb, Lixia Liu, Philip Mollica, III, Barbara Dziegielewska, Daniel W. Lee

Blood (2023) 142 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2023-186464

Published: 2023

Journal Articles

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

Blood (2022) 140 (5): 451–463.

https://doi.org/10.1182/blood.2022015795

Published: 2022

Includes: Supplemental data

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Alan S. Wayne, MD, Gerard Michel, MD, Daniel W. Lee, MD, André Baruchel, MD, Sonali Chaudhury, MD, Patrick A. Brown, MD, Michelle Hermiston, MD PhD, Joerg Krueger, MD, Tong Shen, PhD, Kristy Tailford, PhD, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-137233

Published: 2020

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Robbie G. Majzner, MD, Skyler P. Rietberg, Louai Labanieh, Elena Sotillo, PhD, Evan W. Weber, PhD, Rachel C. Lynn, PhD, Johanna L. Theruvath, MD, Constance M. Yuan, MD PhD, Peng Xu, MD, Sang M. Nguyen, BS, Nirali N. Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Terry J. Fry, MD, Daniel W. Lee, MD, Crystal L. Mackall, MD

Blood (2018) 132 (Supplement 1): 963.

https://doi.org/10.1182/blood-2018-99-115558

Published: 2018

Journal Articles

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

Anandani Nellan, Cynthia M. Lester McCully, Rafael Cruz Garcia, Nalini Jayaprakash, Brigitte C. Widemann, Daniel W. Lee, Katherine E. Warren

Blood (2018) 132 (6): 662–666.

https://doi.org/10.1182/blood-2018-05-846428

Published: 2018

Journal Articles

High Rates of Minimal Residual Disease-Negative (MRD−) Complete Responses (CR) in Adult and Pediatric and Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) Treated With KTE-C19 (Anti-CD19 Chimeric Antigen Receptor [CAR] T Cells): Preliminary Results of the ZUMA-3 and ZUMA-4 Trials

Blood (2016) 128 (22): 2803.

https://doi.org/10.1182/blood.V128.22.2803.2803

Published: 2016

Journal Articles

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, Terry J Fry, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2016) 128 (22): 218.

https://doi.org/10.1182/blood.V128.22.218.218

Published: 2016

Journal Articles

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Haneen Shalabi, DO, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Ling Zhang, PhD, Daniel W. Lee, III, MD, David Stroncek, MD, Crystal L. Mackall, MD, Terry J Fry, MD

Blood (2016) 128 (22): 650.

https://doi.org/10.1182/blood.V128.22.650.650

Published: 2016

Journal Articles

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Haneen Shalabi, DO, Pamela L Wolters, PhD, Staci Martin, PhD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Daniel W. Lee, III, MD, Crystal L. Mackall, MD, Terry J Fry, MD, Nirali N Shah, MD

Blood (2016) 128 (22): 1625.

https://doi.org/10.1182/blood.V128.22.1625.1625

Published: 2016

Journal Articles

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Terry J. Fry, MD, Maryalice Stetler-Stevenson, MD PhD, Nirali N Shah, MD, Constance M. Yuan, MD PhD, Bonnie Yates, RN, PNP, Cindy Delbrook, RN, Ling Zhang, PhD, Daniel W. Lee, III, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 1324.

https://doi.org/10.1182/blood.V126.23.1324.1324

Published: 2015

Journal Articles

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Yinmeng Yang, BS, Tasha Lin, MD, Elad Jacoby, MD, Haiying Qin, MS, Elizabeth Grier Gardner, MD, Christopher Daniel Chien, PhD, Daniel W. Lee, III, MD, Terry J. Fry, MD

Blood (2015) 126 (23): 100.

https://doi.org/10.1182/blood.V126.23.100.100

Published: 2015

Journal Articles

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

David F. Stroncek, MD, Daniel W. Lee, III, MD, Jiaqiang Ren, MD PhD, Marianna Sabatino, MD, Hanh Khuu, MD, Melinda S. Merchant, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 383.

https://doi.org/10.1182/blood.V126.23.383.383

Published: 2015

Journal Articles

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Terry J. Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 684.

https://doi.org/10.1182/blood.V126.23.684.684

Published: 2015

Journal Articles

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Daniel W. Lee, MD, Maryalice Stetler-Stevenson, MD PhD, Marianna Sabatino, MD, Constance Yuan, MD PhD, Terry J Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, Hua Zhang, PhD, Ling Zhang, Nick Tschernia, BS, Yongzhi Cui, MD PhD, Steven Feldman, PhD, James N Kochenderfer, MD, Steven A. Rosenberg, MD, PhD, David F. Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2014) 124 (21): 381.

https://doi.org/10.1182/blood.V124.21.381.381

Published: 2014

Journal Articles

Current concepts in the diagnosis and management of cytokine release syndrome

Daniel W. Lee, Rebecca Gardner, David L. Porter, Chrystal U. Louis, Nabil Ahmed, Michael Jensen, Stephan A. Grupp, Crystal L. Mackall

Blood (2014) 124 (2): 188–195.

https://doi.org/10.1182/blood-2014-05-552729

Published: 2014

Includes: Supplemental data

Journal Articles

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Daniel W. Lee, III, MD, Nirali N Shah, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, Cindy Delbrook, RN, Kelly Richards, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, M.D., Ph.D., David Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2013) 122 (21): 68.

https://doi.org/10.1182/blood.V122.21.68.68

Published: 2013

Journal Articles

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Waleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler-Stevenson, Constance M. Yuan, Ira H. Pastan, Dimiter S. Dimitrov, Richard A. Morgan, David J. FitzGerald, David M. Barrett, Alan S. Wayne, Crystal L. Mackall, Rimas J. Orentas

Blood (2013) 121 (7): 1165–1174.

https://doi.org/10.1182/blood-2012-06-438002

Published: 2013

Includes: Supplemental data

Journal Articles

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD, PhD, Marianna Sabatino, MD, Barbara Tumaini, MS, Kelly Richards, RN, Cindy Delbrook, RN, James N Kochenderfer, M.D., Steven A. Rosenberg, David Stroncek, MD, Crystal L Mackall, MD, Alan S Wayne, MD

Blood (2012) 120 (21): 2609.

https://doi.org/10.1182/blood.V120.21.2609.2609

Published: 2012

NARROW

Expression of a Novel Chimeric Inhibitory Receptor Attenuates CD19 CAR T Cells: A Promising Strategy for Toxicity Mitigation

CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Infectious Complications Associated with CAR T-Cell Therapy

Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

A Prospective Evaluation of Neurocognitive Function and Neurologic Symptoms in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Undergoing Anti-CD22 Chimeric Antigen Receptor Therapy

Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells

Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Current concepts in the diagnosis and management of cytokine release syndrome

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Autologous-Collected Donor-Derived CD19-Directed Chimeric Antigen Receptor (CD19-CAR) T Cells Induce a Complete Remission in Chemotherapy-Refractory Childhood Acute Lymphocytic Leukemia (ALL) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only